Sugi Predict

Sugi Predict / Compounds / SCHEMBL237017

SCHEMBL237017

SCHEMBL237017

CCCCC(CCC)S(=O)(=O)O.[NaH]

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.42
▸ FDPS P14324 1/20 0.37
▸ RECQL P46063 1/20 0.37
▸ CHRM1 P11229 1/20 0.36
▸ AKR1A1 P14550 1/20 0.36
▸ CHRM3 P20309 1/20 0.36
▸ HTR2A P28223 1/20 0.36
▸ HTR2C P28335 1/20 0.36
▸ ADRA1A P35348 1/20 0.36
▸ HRH1 P35367 1/20 0.36
▸ DRD3 P35462 1/20 0.36
▸ SLC6A3 Q01959 1/20 0.36
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC2 Q92769 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ CA2 P00918 3/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ MMP1 P03956 4/20 0.35
▸ MMP7 P09237 4/20 0.35
▸ MMP12 P39900 4/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4350716 0.98 TP53 (0.43) TP53FDPSRECQLCHRM1AKR1A1
SCHEMBL6201439 0.93 TP53 (0.46) TP53FDPSRECQLCA2MAPK1
SCHEMBL8609916 0.91 TP53 (0.48) TP53FDPSCA2CA1
SCHEMBL9660948 0.91 TP53 (0.48) TP53FDPSCA2CA1
SCHEMBL8813654 0.91 TP53 (0.52) TP53FDPSCA2CA1
Ammonia Solution, Strong SCHEMBL28253234 0.91 TP53 (0.45) TP53FDPSRECQLCA2MAPK1
SCHEMBL28084442 0.90 TP53 (0.47) TP53FDPSCA2CA1
SCHEMBL3426182 0.89 TP53 (0.50) TP53FDPSCA2CA1
SCHEMBL7134938 0.89 TP53 (0.50) TP53FDPSCA2CA1
SCHEMBL9011883 0.89 TP53 (0.50) TP53FDPSCA2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200246449-A1 INTRAVENOUS IMMUNOGLOBULIN COMPOSITIONS SPECIFIC FOR RESPIRATORY SYNCYTIAL VIRUS AND METHODS OF MAKING AND USING THE SAME NANOBIO CORPORATION (US) 2020-08-06 — — US claimed
WO-2018204669-A1 INTRAVENOUS IMMUNOGLOBULIN COMPOSITIONS SPECIFIC FOR RESPIRATORY SYNCYTIAL VIRUS AND METHODS OF MAKING AND USING THE SAME NANOBIO CORPORATION (US) 2018-11-08 — — WO claimed
EP-2729169-A1 HUMAN RESPIRATORY SYNCYTIAL VIRUS VACCINE Nanobio Corporation (US) 2014-05-14 — — EP claimed
US-20130011443-A1 HUMAN RESPIRATORY SYNCYTIAL VIRUS VACCINE NANOBIO CORPORATION 2013-01-10 — — US claimed
WO-2013006797-A1 HUMAN RESPIRATORY SYNCYTIAL VIRUS VACCINE NANOBIO CORPORATION (US) 2013-01-10 — — WO claimed
US-20120276182-A1 METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS NANOBIO CORPORATION 2012-11-01 — — US claimed
US-20120219602-A1 METHODS FOR TREATING HERPES VIRUS INFECTIONS NANOBIO CORPORATION 2012-08-30 — — US claimed
US-20120064136-A1 ANTI-AGING AND WRINKLE TREATMENT METHODS USING NANOEMULSION COMPOSITIONS NANOBIO CORPORATION 2012-03-15 — — US claimed
EP-2349209-A2 NANOEMULSION THERAPEUTIC COMPOSITIONS AND METHODS OF USING THE SAME Nanobio Corporation (US) 2011-08-03 — — EP claimed
EP-2293787-A1 NANOEMULSIONS FOR TREATING FUNGAL, YEAST AND MOLD INFECTIONS Nanobio Corporation (US) 2011-03-16 — — EP claimed
US-20100092526-A1 NANOEMULSION THERAPEUTIC COMPOSITIONS AND METHODS OF USING THE SAME NANOBIO CORPORATION 2010-04-15 — — US claimed
WO-2010036938-A2 NANOEMULSION THERAPEUTIC COMPOSITIONS AND METHODS OF USING THE SAME NANOBIO CORPORATION (US) 2010-04-01 — — WO claimed
US-20100075914-A1 METHODS FOR TREATING HERPES VIRUS INFECTIONS NANOBIO CORPORATION 2010-03-25 — — US claimed
US-20090304799-A1 NANOEMULSION INFLUENZA VACCINE NANOBIO CORPORATION 2009-12-10 — — US claimed
US-20090269380-A1 METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS NANOBIO CORPORATION 2009-10-29 — — US claimed
US-20090269394-A1 METHODS AND COMPOSITIONS FOR TREATING ONCHOMYCOSIS NANOBIO CORPORATION 2009-10-29 — — US claimed
WO-2009131995-A1 NANOEMULSION INFLUENZA VACCINE NANOBIO CORPORATION (US) 2009-10-29 — — WO claimed
WO-2009132342-A1 NANOEMULSIONS FOR TREATING FUNGAL, YEAST AND MOLD INFECTIONS NANOBIO CORPORATION (US) 2009-10-29 — — WO claimed
WO-2009132343-A1 NANOEMULSIONS FOR TREATING ONCHOMYCOSIS NANOBIO CORPORATION (US) 2009-10-29 — — WO claimed
WO-2009129470-A2 METHODS FOR TREATING HERPES VIRUS INFECTIONS NANOBIO CORPORATION (US) 2009-10-22 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090269394-A1 METHODS AND COMPOSITIONS FOR TREATING ONCHOMYCOSIS DPM1, ERG28, POLR1C TP53 200/4885FDPS 188/4885RECQL 1432/4885
US-20100092526-A1 NANOEMULSION THERAPEUTIC COMPOSITIONS AND METHODS OF USING THE SAME CFTR, CCL11, ELANE TP53 667/4885FDPS 647/4885RECQL 1411/4885
US-20100075914-A1 METHODS FOR TREATING HERPES VIRUS INFECTIONS STING1, IFNG, NGF TP53 755/4885FDPS 3272/4885RECQL 1156/4885
US-20090269380-A1 METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS DPM1, ERG28, CYP51A1 TP53 1962/4885FDPS 254/4885RECQL 1517/4885
US-20120219602-A1 METHODS FOR TREATING HERPES VIRUS INFECTIONS STING1, IFNG, NGF TP53 755/4885FDPS 3272/4885RECQL 1156/4885
US-20120276182-A1 METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS DPM1, ERG28, CYP51A1 TP53 1962/4885FDPS 254/4885RECQL 1517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.